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Cardiovascular disease (CVD) is an increasing world health problem. Traditional risk factors fail to account for all deaths from
CVD. It is mainly the environmental, dietary and lifestyle behavioral factors that are the control keys in the progress of this
disease. The potential association between chronic heavy metal exposure, like arsenic, lead, cadmium, mercury, and CVD has been
less well deﬁned. The mechanism through which heavy metals act to increase cardiovascular risk factors may act still remains
unknown, although impaired antioxidants metabolism and oxidative stress may play a role. However, the exact mechanism of
CVD induced by heavy metals deserves further investigation either through animal experiments or through molecular and cellular
studies. Furthermore, large-scale prospective studies with follow up on general populations using appropriate biomarkers and
cardiovascular endpoints might be recommended to identify the factors that predispose to heavy metals toxicity in CVD. In this
review, we will give a brief summary of heavy metals homeostasis, followed by a description of the available evidence for their link
with CVD and the proposed mechanisms of action by which their toxic eﬀects might be explained. Finally, suspected interactions
between genetic, nutritional and environmental factors are discussed.
1.Introduction
The potential association between chronic heavy metal ex-
posure and cardiovascular disease (CVD) has a number of
implications. Although the cardiovascular system is not typ-
ically viewed as a primary target of heavy metal toxicity,
review articles covering their role as cardiovascular toxicant
are scant, and the prime concern of most reviews has focused
on the imbalance in the antioxidant protective mechanisms
leading to oxidative stress in the cells as a major eﬀect of
their environmental exposure. Altered gene expression by
environmental inﬂuence, particularly dietary components
over gene regulation is expected to be responsible for heavy
metal toxicity.
I nt h i sp a p e r ,w ew i l lg i v eab r i e fs u m m a r yo fh e a v y
metals homeostasis, followed by a description of the avail-
able evidence for their link with CVD and the proposed
mechanisms of action by which their toxic eﬀects might be
explained. Finally, suspected interactions between genetic,
nutritional, and environmental factors are discussed.
2.The Prevalenceof CVD and ItsRisk Factors
Despite recent signiﬁcant advances in the treatment of CVD,
it remains the number one cause of death in the developed
worldandaccountsforalmostonemillionfatalitieseachyear
in United States alone [1]. CVD also accounts for 82% of
deaths in the developing countries [2]. The annual mortality
rate of CVD is expected to reach 23.6 million deaths by 2030
[3]. The traditional risk factors for CVD do not account for
all deaths [4]. Environmental, dietary, and lifestyle factors
appear to be important, accounting for the dramatic recent
changes in prevalence and would be of wide public health
signiﬁcance.
Confounding variables eﬀects are being now evaluated as
potential mediators (i.e., in the biological causal pathway),
moderators (i.e., risk modiﬁers), direct causes, or otherwise
parts of complex causal pathways [5]. These pathways
can include connections between individual-level indicators
(e.g., age, sex, race/ethnicity, socioeconomic status); behav-
ioral risk factors (e.g., dietary habits); biological factors (e.g.,2 Journal of Toxicology
genetics); social factors; heavy metals dose (i.e., both recent
and cumulative); health conditions (e.g., diabetes, heart dis-
ease, and hypertension); other biological markers predictive
of disease (e.g., homocysteine levels) that may be thought
of as either outcomes by themselves or as intermediate
pathological states that result in other conditions (e.g., renal
dysfunction, cognitive declines).
The spectrum of risk factors for CVD ranges from purely
genetic to behavioural and environmental factors in the
broadest sense (Table 1). CVD is initiated by a coincidence
of diﬀerent risk factors. The latter two already show that
behaviour and the environment (including the composition
of nutrition) play an essential role in the majority of CVD.
Patients diﬀer in the time of onset, dynamics, and outcomes
of CVD, indicating the complex pathophysiology of CVD.
Diﬀerent, genetically determined susceptibilities to environ-
mental risk factors, interactions of the cardiovascular system
with other organs like the immune system, and possible
interactions between these risk factors within an individual
are the likely causes of those diﬀerences. Despite an increas-
ing understanding of genes, proteins, signalling pathways,
cell-cell interactions, and systemic processes involved in
CVD (initiation, progression, and outcome), the relevance
of environmental factors is hardly investigated.
3 .T h eM ec h an is m so fA t h e r og e n e s is
Atherogenesis is a multifactorial pathophysiological process
of the arterial vasculature, which is characterized by pro-
gression from inﬂammation and smooth muscle cell pro-
liferation to late stages that are marked by thrombotic
and ﬁbrotic obliterations of the vessels. Dysfunction of the
endothelial cells leads to a series of events including in-
ﬂammatory cell inﬁltration, platelet-thrombus formation,
impaired nitric oxide (NO) homeostasis in the vessel and
concomitant alteration of the cellular redox state [32].
Oxidized LDL particles are readily taken by macrophage
scavenger receptors, leading to “foam cell” formation, that
precedes atheroma development. Lipid aldehydes derived
from LDL oxidation can also modulate expression of genes
coding inﬂammatory mediators and adhesion molecules
[33]. Reactive oxygen species can also function as signal-
ing molecules that help to induce the activity of nuclear
transcription factors such as nuclear factor Kappa B (NF-
κB). The increased activity of these transcription factors is
associatedwithupregulationofvascularadhesionmolecules-
1 (VCAM-1), cytokines such as interleukin-1beta (IL-1β)
and tumor necrosis factor alpha (TNF-α) and chemokines
including monocyte chemoattractant protein (MCP)-1 and
interleukin (IL)-8 in the endothelium [34]. Many risk
factors, including cigarette smoking, hypertension, diabetes
mellitus, and hypercholesterolemia, can induce atherogene-
sisbymodulationofinﬂammatorypotential,oxidativestress,
or NO perturbations in the endothelium.
There are several hypotheses to explain the initiation
of CVD. Cumulative evidence from a large number of
studies indicates that inﬂammation plays a pivotal role in
atherosclerotic plaque formation [35]. Based on current
knowledge, the hypothesis that best explains atherosclerosis
pathophysiology is the “response to injury hypothesis” [34].
Lipid peroxidation is initiated by free radicals (e.g., super-
oxide anion, hydrogen peroxide, and lipid peroxide), which
are produced in the body primarily as a result of aerobic
metabolism[36,37].Transitionmetalions,particularlydiva-
lent ions such as iron and copper, can further catalyze highly
reactive free radicals formation in Fenton-type reactions
[38]. LDL modiﬁcation by oxidative damage is considered
to be a key event in the development of atherosclerosis,
and oxidized LDL particles are found in atherosclerotic
lesions [33]. Although existing literature is limited, there
are several mechanisms pointing to the atherogenic eﬀects
of heavy metals exposure by which they can promote lipid
peroxidation and subsequent atherosclerosis.
4.The ToxicEffects of HeavyMetals
Heavy metals are commonly deﬁned as those having a
speciﬁc density of more than 5g/cm3 such as lead, mercury,
aluminum, arsenic, cadmium, nickel. They are widely dis-
tributed in the earth’s crust, but present at very low con-
centrations in the body. Their presence in the atmosphere,
soil, and water, even in traces, can cause serious problems
to all organisms. Their main impact on human health is
principally through occupational exposure, environmental
contamination, and accumulation in food, mainly in veg-
etables grown on contaminated soil. Arsenic and cadmium,
in addition to mercury and lead, have been identiﬁed as the
mostprobablecausesofheavymetal-relateddiseaseobserved
in primary care medicine [39]. Exposure to one heavy metal
contaminant is often accompanied by exposure to others. It
is, therefore, expected that joint interactions may occur in
populations exposed to mixtures of metals.
Heavy metals are toxic because they may have cumula-
tive deleterious eﬀects that can cause chronic degenerative
changes [40], especially to the nervous system, liver, and
kidneys, and, in some cases, they also have teratogenic and
carcinogenic eﬀects [41]. The mechanism of toxicity of some
heavy metals still remains unknown, although enzymatic
inhibition, impaired antioxidants metabolism, and oxidative
stress may play a role. Heavy metals generate many of their
adverse health eﬀects through the formation of free radicals,
resulting in DNA damage, lipid peroxidation, and depletion
of protein sulfhydryls (e.g., glutathione) [42].
The importance of these metals as environmental health
hazards is readily evident from the fact that they ranked
in the top 10 on the current Agency for Toxic Substances
and Disease Registry Priority List of Hazardous Substances
[43]. This listing is based on the toxicity of the substance
and the potential for exposure from air, water, or soil
contamination. As a result of the extensive use of these
metals and their compounds in industry and consumer
products, these agents have been widely disseminated in the
environment.Becausemetalsarenotbiodegradable,theycan
persist in the environment and produce a variety of adverse
eﬀects. Maximum levels for heavy metals in food have been
set in consideration for possible chemical contaminants.Journal of Toxicology 3
Table 1: Classiﬁcation of CVD risk factors.
Category Examples References
Nonmodiﬁable risk factors
(i) Advancing age
(ii) Male gender
(iii) Family history/genotype
(i) [6]
(ii) [7]
(iii) [8]
Metabolic risk factors
(i) Hypertension
(ii) Diabetes mellitus/glucose intolerance
(iii) Metabolic syndrome
(iv) Hyperlipidemias
(v) Obesity/overweight
(i) [9]
(ii) [10]
(iii) [11]
(iv) [12]
(v) [13]
Lifestyle risk factors
(i) Smoking
(ii) Physical activity
(iii) Diet
(i) [14]
(ii) [15]
(iii) [16, 17]
Novel risk factors
(i) Lipoprotein (a)
(ii) Homocysteine
(iii) Inﬂammatory markers (e.g., C-reactive protein)
(iv) Prothrombotic factors (e.g., ﬁbrinogen)
(v) Trace elements (e.g., selenium, zinc, copper, chromium)
(vi) Heavy metals (e.g., arsenic, lead, cadmium, mercury)
(i) [18]
(ii) [19]
(iii) [20–23]
(iv) [24–27]
Although contaminated food may contain environmental
toxins, they are also a very important source of nutrients,
for example omega 3 fatty acids, which may prevent chronic
diseases like CVD. Thus, an attempt has been made to
allow people to obtain the beneﬁcial health eﬀects of natural
food without excessive exposure to possible contaminants.
Evaluations of heavy metals toxicity have been made by sev-
eral international bodies, like the Center of Disease Control
(CDC), World Health Organization (WHO), Occupational
Safety and Health Administration (WHO-OSHA), Interna-
tional Programme on Chemical Safety (WHO-IPCS), Joint
FAO/WHO Expert Committee on Food Additives (JECFA),
and International Agency for Research on Cancer (IARC)
(Table 2). Some of them have been classiﬁed as carcinogens
of category 1 (cadmium). Currently, there are insuﬃcient
data to set a threshold value above which heavy metals would
exert their negative eﬀects. Deﬁning this threshold might be
f r a u g h tw i t hd i ﬃculties since it might well be population-
dependent due to diﬀerences in the population intake of
dietary antioxidants or diﬀerences in their genetic-based
defenses.
5. PotentialSources of Heavy
Metals Contamination
The toxicity of heavy metals at high levels of exposure is
well known, but a current concern is the possibility that
continual exposure to relatively low levels of heavy metals
may lead to chronic adverse health eﬀects. Despite an overall
decrease in human exposure to heavy metals in recent years,
the potential for high intake of these contaminants still exists
at many homes and in many occupational settings. Cosmetic
products like lipsticks, eye makeup, Talcum powder, and
skin lightening creams are potential sources of heavy metals
exposure [44]. The presence of lead has been reported in
traditional eye cosmetics such as Kohl and Surma [45].
Henna, a traditional plant product applied as temporary
paint-on tattoos and hair dying, is reported to be very rich
i nh e a v ym e t a l ss u c ha sm e r c u rya n dl e a d[ 46]. Other hidden
sources may include ethnic folk remedies, toys, and certain
imported candies and spices, [47–49]. Bottled Zamzam holy
water, which is made available to pilgrims on sale, has been
taken oﬀ the market recently for containing high levels
of arsenic [50]. Tobacco plants have a special ability to
absorb cadmium from soil and to accumulate it in the leaf
[51]. Smoking of cigarettes and Shisha (hookah, narghile), a
widely used smoking device in Saudi Arabia, is an important
exposure route to cadmium [52].
6.The MetabolicEffects ofHeavyMetals
Theknowledgegainedaboutthehomeostasisofheavymetals
has been substantial over more than a decade. Although they
havenoknownmetabolicfunction,whenpresentinthebody
they disrupt normal cellular processes, leading to toxicity
in a number of organs. They are relatively poorly absorbed
into the body, but once absorbed are slowly excreted
and accumulate in the body causing organ damage. Thus,
their toxicity is in large part due to their accumulation
in biological tissues, including food animals such as ﬁsh
and cattle as well as humans. Distribution of heavy metals
in the body relies on its binding to carrier molecules in
the circulation. Metallothioneins are small proteins rich in
cysteine residues, which accounts for the unique metal-
binding properties of metallothioneins and play a major role
in the dispersal and storage of heavy metals in the body.
They also accumulate in hair and toenails (e.g., arsenic and
mercury), which both can be used as indicators of long-term
exposure in population studies. These heavy metals have a
slow excretion rate from the body, as indicated by their long
half-life time (e.g., half-life of lead is 27 year in cortical bone
and16yearincancellousbone,half-lifeofcadmiumis 10–30
years), compared with their uptake rate.4 Journal of Toxicology
Table 2: Noncardiovascular harmful eﬀects of heavy metals.
Heavy metal Most aﬀected organs Chronic health eﬀects References
Arsenic
(i) Central nervous system
(ii) Lungs
(iii) Digestive tract
(iv) Circulatory system
(v) Kidneys
(i) Cancers
(ii) Peripheral vascular disease, which in its
extreme form leads to gangrenous changes (black
foot disease, only reported in Taiwan)
(iii) Skin lesions (melanosis, keratosis)
(iv) Hearing loss
(v) Reproductive toxicity
(vi) Hematologic disorders
(vii) Neurological diseases
(viii) Developmental abnormalities and
neurobehavioral disorders
[28]
Lead
(i) Central nervous system
(ii) Erythropoiesis
(iii) Kidneys
(iv) Liver
(i) Cancers
(ii) Kidney damage
(iii) Neurological diseases
(iv) Impaired intellectual ability and behavioral
problems in children
[29]
Cadmium
(i) Kidneys
(ii) Bone
(iii) Liver
(iv) Lungs
(i) Cancers
(ii) Kidney damage
(iii) Bronchiolitis, COPD, emphysema, ﬁbrosis
(iv) Skeletal damage, ﬁrst reported from Japan,
the itai-itai (ouch-ouch) disease (a combination
of osteomalacia and osteoporosis)
[30]
Mercury
(i) Central nervous system
(ii) Kidneys
(iii) Liver
(iv) Lungs
(i) Lung damage
(ii) Kidney damage
(iii) Neurological diseases
(iv) Impaired intellectual ability and behavioral
problems in children
(v) Metallic mercury is an allergen, which may
cause contact eczema
(vi) Mercury from amalgam ﬁllings may give rise
to oral lichen
[31]
6.1. Arsenic. After ingesting inorganic arsenic compounds,
the absorbed arsenic is metabolized primarily by the liver
and excreted by the kidneys into the urine within a few
days after exposure. Organic arsenic species in ﬁsh are
also rapidly absorbed. In comparison to inorganic forms,
organic compounds are much less extensively metabolized
in the human body and more rapidly eliminated in urine
with less than 5% was found to be eliminated in feces. In
addition to gastrointestinal, dermal, or pulmonary uptake,
exposure to organic arsenic species originates from methy-
lation of inorganic arsenic inside the human body, which is
regardedasadetoxiﬁcationmechanism,sincethemethylated
metabolites exert less acute toxicity and reactivity with
tissue constituents than inorganic arsenic. The central site
for arsenic methylation in the human body is the liver.
These methylated metabolites can be eliminated in the bile.
Factors such as dose, age, gender, and smoking contribute
only minimally to the large interindividual variation in
arsenic methylation observed in humans (reviewed by [53]).
6.2. Lead. The gastrointestinal absorption of lead is higher
for children (30–50%) than for adults (5–10%). The ab-
sorbed lead is distributed to blood, soft tissue, and bone. In
blood, red blood cells virtually bind all of the lead (98-99%),
thusonly1-2%ofbloodleadarepresentinplasma.Gastroin-
testinal absorption and retention, the major pathway of lead
intake, have been shown to vary widely depending on the
chemicalenvironmentofthegastrointestinallumen,age,and
iron stores (nutritional status of the subject). Certain dietary
components may act by increasing lead solubility, such as
ascorbic acid, amino acids, vitamin D, protein, fat, and
lactose, thus enhancing its absorption. Total body content
of lead does not have a feedback mechanism which limits
its absorption. Absorbed lead is mainly excreted in urine,
whereas the feces contain predominantly unabsorbed lead.
Being one of the calcium-like elements, lead follows the
movement of calcium in the body to a large extent, and
physiologic regulators of calcium metabolism usually aﬀect
the behavior of lead in a similar manner. Although bone
has been considered a storage site for more than 90% of
the total body burden, increased bone turnover in times of
physiological (e.g., pregnancy or lactation) and pathological
(e.g., osteoporosis) conditions release lead from bone. Lead
can be remobilized from bone by competing with calcium
for transport and for binding sites and is released, along
with calcium, when bone is resorbed (reviewed by [54]).
The mechanisms by which both elements enter and leave the
bone are similar and through these mechanisms, bone lead
equilibrates with blood lead [55].Journal of Toxicology 5
6.3. Cadmium. The possible range of intestinal absorption
rate for cadmium was established to be between 3 and 7%
in humans and was used to assign an average 5% absorption
rate in deriving a safe exposure level [56]. However, higher
cadmium absorption rates (20–40%) were observed among
youngsubjectsandconsideredbiliaryexcretionandreuptake
via enterohepatic circulation to be the most likely possible
reason. The duodenal iron transporter is upregulated by iron
deﬁciency, which leads to an increased intestinal absorption
of dietary cadmium. This is probably the main reason why
the body burden of cadmium is generally higher among
women [57] whose prevalence of iron depletion is higher
than that of men. Once absorbed, cadmium binds avidly to
metallothionein. Cadmium irreversibly accumulates in the
human body, particularly in kidneys and liver. Because there
is no eﬃcient excretory mechanism for cadmium from the
body and it is bound with high aﬃnity to metallothionein
within cells. Accumulation of cadmium mainly in liver and
kidney and also in testes is due to the ability of these
tissues to synthesize metallothionein, a cadmium-inducible
protein that protects the cell by tightly binding the toxic
cadmium ion. The kidney is regarded as critical organ for its
accumulation and toxicity. Greater than one-third of body
cadmium deposits are found in the kidney, especially in
subjects with low environmental exposure. By far, the most
toxicological property of cadmium is its exceptionally long
half-life in the human body and thus its low excretion rate
(reviewed by [30]).
6.4. Mercury. Dietary methylmercury is well absorbed from
the gastrointestinal tract, readily enters the bloodstream, and
is distributed to all tissues. About 5% of the body load is
found in the blood compartment, and about 10% is found
in the brain. 95% of the methylmercury in blood is bound
to erythrocytes leaving 5% present in plasma. Less than 1%
of the body burden of methylmercury is excreted per day,
mainly via the feces. In the body, methylmercury is mainly,
if not exclusively, bound to the sulfur atom of thiol ligands.
Methylmercury is metabolized to inorganic mercury prior
to elimination via feces, but the rate of conversion is slow
(the half-life is about 70–80 days). In the liver and kidney,
it is rapidly converted to inorganic mercury and stored as
divalent mercury cation. This, together with the fact that
the human body has no way of excreting mercury actively,
means that mercury continues to accumulate in the body
throughout life (reviewed by [31]).
7. Health HarmfulEffects of Heavy Metals
Theseverityofadversehealtheﬀectsisrelatedtothechemical
formofheavymetalsandisalsotimeanddosedependent.As
mentioned earlier, heavy metals as environmental pollutants
and promoters of oxidative stress are associated with a mul-
titude of disadvantageous impacts on human health. There
is a growing concern about the physiological and behavioral
eﬀects of environmental heavy metals in human population.
Human intoxication has both acute and chronic eﬀects on
health and environment (Table 2). Albeit the toxicity of
hea vymetalsathighlev elsofexposureiswellkno wn,amajor
concern of today is the possibility that continual exposure
to relatively low levels of heavy metals may entail adverse
health eﬀects. Nevertheless, their contribution to CVD is
still incompletely understood. Recent studies have shown
that vascular eﬀects of heavy metals may contribute to a
variety of pathologic conditions including diabetes mellitus
and hypertension [58, 59]. Mechanisms of action after heavy
metal intoxication are less well studied and are still unclear.
7.1. Arsenic. Elemental arsenic is a metalloids found ubiq-
uitously in nature. Humans are exposed to arsenic through
medicinal, environmental, and occupational sources. Both
organicandinorganicarsenicarepresentinvariousamounts
in food-like marine ﬁsh. Organic forms are arsenobetaine,
whichaccountfor90% ormoreofthetotalarsenic in marine
ﬁsh, and arsenocholine, in smaller amounts. However,
inorganic forms of arsenic are much more toxic than the
organic forms. Arsenic can exist in four valency states,
trivalent (AsIII) and pentavalent (AsV) arsenic are the major
inorganic forms in natural water, whereas minor amounts of
monomethylarsonic acid (MMA) and dimethylarsinic acid
(DMA) can also be present. In the general population, the
main exposure to inorganic arsenic is through ingestion of
high-arsenic drinking water [60]. The safety level of arsenic
in drinking water has been lowered from 50 to 10 ppb by the
US Environmental Protection Agency [61].
Chronic arsenic intoxication seems to be an impor-
tant public health problem in India, Bangladesh, Chile,
Argentina, Hungary, Japan, and China [62]. Both environ-
mental and occupational exposures to inorganic arsenic have
been related to an increased cardiovascular mortality [63,
64]. Arsenic has been documented as the major risk factor
of black foot disease, a unique peripheral vascular disease
identiﬁed in endemic areas of arseniasis in Taiwan. However,
other forms of peripheral vascular diseases have been shown
to be caused by arsenic in other studies from several other
countries.
Clinical studies have also reported other arsenic-induced
cardiovascular eﬀects including hypertension, diabetes mel-
litus, atherosclerosis, coronary heart disease, and stroke in
a dose-dependent manner [65, 66]. Previous reviews of the
role of arsenic in CVD were supportive of the possibility
of an association, but the evidence was inadequate to
establish a causal-eﬀect relationship. A causal inference may
be established if the data had a stronger eﬀect in a susceptible
subgroup of the population.
7.1.1. Epidemiological Evidence. The studies on arsenic-
induced CVD were either occupational cohort studies or
ecological correlation studies. Although epidemiological
studies conducted in general populations strongly support
long-term arsenic exposure as an independent risk factor for
CVD, the studies of occupational populations are inconclu-
sive [67]. Methodological problems might limit the causal
interpretation of this relationship. Occupational studies may
be subject to biases resulting from the healthy worker eﬀect,
which may underestimate the arsenic-related risk due to6 Journal of Toxicology
the fact that the severely ill are ordinarily excluded from
employment, and multiple exposure to various chemicals,
and the correlation studies may have the problem of ec-
ological fallacy. The limitation of nonoccupational studies
includes the number of potential participants, accurate
diagnosis of the cardiovascular endpoints, heterogeneity of
exposure resources, limited exposure range which might be
a challenge for epidemiological studies to have a valid long-
term exposure measures, and interindividual variability to
the cardiovascular eﬀect of arsenic exposure.
Nonetheless the dose-response relationship and the bio-
logical plausibility for the association indicate that chronic
arsenic poisoning is an independent risk factor for ath-
erosclerosis [27]. Few epidemiologic studies in the US have
reported the association of arsenic exposure with cardiovas-
cularendpoints atlow to moderate chronic levels in drinking
water [68, 69]. Higher prevalence of ischemic heart diseases
was found in subjects with cumulative arsenic exposure from
drinking water, which was used as a marker of long-term
exposure dosage, when compared to control subjects after
multivariate adjustment [66]. Similarly, higher prevalence of
hypertension was found among residents in endemic areas in
Bangladesh of chronic arsenicism compared with those from
nonendemic areas [70]. Inorganic arsenic exposure from
drinking water, but not for the cumulative arsenic exposure,
is also associated with an increased risk of developing type 2
diabetes mellitus [71]. Although hypertension and diabetes
mellitusmaypartlyexplainthehigherriskofCVDassociated
with arsenic exposure, the atherosclerotic eﬀect of arsenic is
independent because such an association persists even after
controlling for the confounding eﬀect of both factors. How-
ever, correcting for confounders in epidemiological studies is
extremely challenging and is unlikely to completely account
for their potential eﬀects. An ecological study, conducted
in the arseniasis-endemic areas of southwestern Taiwan,
reported increased age-adjusted mortality from ischemic
heart diseases compared with residents in nonendemic
areas [64]. In Chile, acute myocardial infarction mortality
increased following a period of high exposure to arsenic in
drinking water and decreased after arsenic remediation had
been implemented [72]. Likewise in southwestern Taiwan,
mortality rates from ischemic heart disease were declining
after the cessation of consumption of high arsenic well water
[73]. However, results from studies conducted in endemic
areas with chronic long-term arsenic exposure may limit the
applicabilitytootherpopulations,especiallythosewithlower
levels of arsenic exposure.
Except for a few studies using a prospective follow-up
design, most are observational and cross-sectional. However,
most of the existing epidemiological studies were conducted
in populations with high levels of arsenic exposure, and
little is known about the associations between chronic low
level arsenic exposure via drinking water and CVD [74].
Furthermore, the heterogeneity of drinking water resources
and the limited exposure range together pose a challenge for
epidemiological studies to be conducted in other areas with
low to moderate arsenic exposure levels that are relevant for
most parts of the world and to have valid long-term arsenic
exposure measures at the individual level.
7.1.2. Mechanism of Action. One of the suggested mecha-
nisms by which arsenic exerts its toxic eﬀect is through an
impairment of cellular respiration by inhibition of several
carbohydrates enzymes (i.e., gluconeogenesis and glycolysis
pathways) and the uncoupling of oxidative phosphorylation
[75]. This might explain the link between acute arsenic
exposure and diabetic risk through its inﬂuence on the
expression of gene transcription factors that are related
to insulin pathways, such as, insulin upstream factor 1
(IUF-1) in pancreatic cells or peroxisome proliferative-
activated receptor γ (PPARγ) in preadipocytes. Arsenic
could also inﬂuence diabetes development by other mech-
anisms, including oxidative stress, inﬂammation, or apop-
tosis, nonspeciﬁc mechanisms that have been implicated in
the pathogenesis of type 2 diabetes [76]. Future research
should evaluate whether these mechanisms mediate the role
of arsenic in diabetes development.
Other studies have suggested the involvement of oxida-
tive stress in the pathogenic eﬀects of arsenic exposure
[77]. Available data suggest an important arsenic role based
on a range of eﬀects related to oxidative stress and vas-
cular inﬂammation. Findings from mechanistic studies in
animal/experimental studies suggest that arsenic causes
inﬂammation in vascular tissues and activates oxidative sig-
naling. The expression of chemokines and proinﬂammatory
cytokines like monocyte MCP-1 and IL-6 has been induced
in vitro by sodium arsenite in vascular lesions [78]. These
observationsareconsistentwithstudiesillustratingincreased
expression of circulating lymphocyte MCP-1 mRNA and
plasma MCP-1 concentration in humans exposed to arsenic
[79]. A more recent study also shows that occurrence of
carotid atherosclerosis among subjects with genotypes of
ApoE and MCP1 when exposed to high arsenic in drinking
water [80].
Experimental studies have suggested that arsenic in-
creases the production of reactive oxygen species [81]. In-
creased accumulation of arsenic in the vessel wall and
increased atherosclerotic lesion formation were observed in
the aorta of female ApoE-knockout mice given drinking
water containing high concentrations of sodium arsenite
without increasing plasma cholesterol. Characterization of
these lesions illustrated increased macrophage accumulation
and ﬁbrosis in arsenic-exposed mice as compared to water-
fed controls [82]. However, very little is known about the
biochemical mechanisms by which low levels of arsenic
exerts its proatherogenic eﬀects.
Oxidative stress has been implicated in the pathophys-
iology of atherosclerosis [34]. The inﬂammatory process
may be involved in the arsenic-induced atherosclerosis as
shown by positive association between blood arsenic with
plasma level of reactive oxidants (superoxide (O2
–)a n dh y -
drogen peroxide (H2O2)) and by a negative association
with antioxidant capacity [83]. Arsenic-induced oxidants,
superoxide, and hydrogen peroxide have been implicated in
in vitro studies [77]. Several cytokines and growth factorsJournal of Toxicology 7
involving inﬂammation were upregulated in persons with
an increased arsenic exposure [79]. In individuals with
arsenic-related skin lesions in Bangladesh, plasma levels of
systemic inﬂammation and endothelial dysfunction markers
(such as sICAM-1 and sVCAM-1) were positively associated
with serum arsenic concentrations [84]. Markers of systemic
inﬂammation and endothelial dysfunction were found to be
predictive for CVD [85]. Thus, suggesting a possible mech-
anism through which long-term arsenic exposure may aﬀect
CVD development. Thus the biomarkers of early biological
eﬀects of ingested inorganic arsenic may include blood levels
of reactive oxidants and antioxidant capacity, inﬂammatory
molecules, as well as cytogenetic changes.
Oxidized lipids are present in all stages of atherogenesis,
and they generate several bioactive molecules (e.g., peroxides
and isoprostanes), of which aldehydes (Malondialdehyde
and 4-hydroxy-trans-2-nonenal) are the major end products
[86]. Increased plasma levels of free lipid aldehydes and
increased accumulation of their protein adducts in ath-
erosclerotic lesions were detected in experimental animals
[87]. Since lipid aldehydes are highly reactive and can
increase monocyte adhesion, cytokine production, and lipid
uptake by scavenger receptors, it is conceivable that excessive
generation of these aldehydes or decreased detoxiﬁcation
upon arsenic exposure exacerbates atherosclerotic lesion
formation [88].
7.1.3. Combination of Gene-Environmental-Nutrient Interac-
tions. Arteriosclerosis can occur following chronic arsenic
poisoning irrespective of traditional coronary risk factors
[89]. However, one would not expect every arsenic-exposed
individual to develop CVD. This implies that other factors
might aﬀect the development and progression of arsenic-
induced CVD. The epidemiological literature to date sug-
gests that the cardiovascular eﬀects of arsenic exposure
are modiﬁed by nutritional factors, genetics, and arsenic
metabolismcapacity.Thesestudieshaveclinicalimplications
onthemanagementandpreventionofarsenic-inducedCVD.
It is known that both genetic and acquired susceptibility may
modify the risk of arsenic-induced CVD [90].
Plausible mechanisms for the eﬀect of arsenic on CVD
include oxidative stress as previously explained, antiox-
idant enzymatic inhibition such as glutathione reduc-
tase, glutathione S-transferase, and glutathione peroxidase,
and altered gene regulation, which might be implicated in
the endogenous defense against arsenic’s eﬀect. Glutathione
S transferases (GSTs) are a superfamily of enzymes that is
important for the detoxiﬁcation reactions in xenobiotic me-
tabolism and plays a major role in cellular antioxidant
defense mechanisms [91]. Glutathione has also been sug-
gested to be a necessary component for arsenic metabolism
probablyintheinitialreductionofarsenatetoarseniteandin
subsequentoxidativemethylation.Inalargestudyconducted
in northeastern Taiwan with low-to-moderate exposure,
the prevalence of carotid atherosclerosis was signiﬁcantly
associated with the genetic polymorphism of GST; P1 and
p53 [92]. The induction of oxidative stress by arsenic may
inﬂuence gene expression, inﬂammatory responses, and
endothelial NO homeostasis [93], which play an important
role in maintaining vascular tone [94]. A causal relationship
was suspected in a study on human gene expression related
to arsenic-associated atherosclerosis among residents of
endemic areas in Taiwan. Signiﬁcant diﬀerences in gene
expression,encodingforseveralcytokinesandgrowthfactors
involving inﬂammation such as IL-1β, IL-6, and matrix
metalloproteinase 1, were found among groups with varying
prolonged exposure levels to arsenic [79]. In a small study in
residents of a high-exposed area in Taiwan, genes encoding
for antioxidant enzymes, like NOS3, the gene for endothe-
lial nitric oxide synthase; SOD2, the gene for manganese
superoxide dismutase, and CYBA, the gene for p22 phox [a
critical enzyme for superoxide production and an essential
component of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase (NOX)], were found to be signiﬁcantly
associated with hypertension risk [95].
Several nutritional factors were investigated in relation to
arsenicrelatedcardiovasculareﬀects.Seleniumisanutrition-
ally trace element that has been known as an antagonist of
arsenic toxicity [96]. Being also protective against oxidative
stress, selenium supplementation was found to be eﬀective
in treating arsenism, an endemic chronic arsenic poisoning
condition in China [97]. Consistent with this, some dietary
deﬁciencieswerefoundtointeractwitharsenic.Forexample,
poor dietary selenium and zinc have been suggested as an
underlying factor for arsenic toxicity in Taiwan and Bang-
ladesh, well-known regions for their reduced selenium and
zinc status worldwide [98].
Low serum carotene level has been suspected to increase
the susceptibility to cardiovascular eﬀects of arsenic expo-
sure among residents of southwestern Taiwan villages with
chronic arsenic exposure [99]. However, the potential
mechanisms involved in the protective action remain to
be studied. In the Health Eﬀects of Arsenic Longitudinal
Study (HEALS) in Bangladesh, the eﬀect of low-level
arsenic exposure on blood pressure was found to be highly
correlated and was more pronounced in persons with
lower intake of other micronutrients with known anti-
oxidant action [100]. Arsenic exposure in the presence
of inadequate intake levels of B vitamins and folic acid
may aﬀect blood pressure through its eﬀect on the for-
mation of S-adenosylhomocysteine and homocysteine. His-
torically, methylation of arsenic has been regarded as a
detoxiﬁcation pathway that takes place in the liver [101]
and requires the conversion of S-adenosylmethionine to S-
adenosylhomocysteine, which subsequently forms homocys-
teine, which requires suﬃcient levels of vitamin B2, B12, B6,
and folic acid in body to be metabolized. Hyperhomocys-
teinemia, a novel cardiovascular risk factor [102], has been
associated with high blood pressure [103]. Hence arsenic
may contribute to the increase of homocysteine levels by
consuming the S-adenosylmethionine pool and therefore
enhance the subsequent cardiovascular risk.
Nevertheless, it is conceivable to presume that the ﬁnd-
ings from Taiwan and Bangladesh may not be generalizable
to other populations due to several potential reasons like
variations in the distribution of polymorphisms in genes
involvedinarsenicmetabolismorresponse[104],diﬀerences8 Journal of Toxicology
in arsenic species to which populations were exposed or
other coexposures [105].
7.2. Lead. Lead exposure assessments have been based on its
intake from food, water, or air. Possible routes for lead expo-
sure are inhalation and swallowing. The four main sources
of contamination of food are soil, industrial pollution,
agricultural technology, and food processing. Worldwide,
there are six sources that account for most cases of lead
exposure: gasoline additives, food-can soldering, lead-based
paints, ceramic glazes, drinking water pipe systems, and folk
remedies [106]. Depending on the source, the concentration,
and the bioavailability of lead determined by the physical
and chemical form of lead, the relative contribution of each
source may vary considerably. Although important measures
have been implemented in a number of countries to decrease
e n v i r o n m e n t a ll e a de x p o s u r es u c ha st h eu s eo fu n l e a d e d
gasoline, removal of lead from paint, solder of canned foods,
andglazedceramicsusedforstorageandpreparationoffood,
it is still a major environmental health problem in speciﬁc
communities and targeted high-risk populations.
Even though safety standards of the WHO-OSHA for
blood lead in workers have been established at 40μg/dL, no
safe level of lead exposure has yet been deﬁned, as health
risks associated with lead are found at ever lower doses. The
CDC statement concerning lead poisoning in young children
redeﬁned elevated blood lead levels as that ≥10μg/dL and
recommended a new set of guidelines for treatment of lead
levels ≥15μg/dL [107]. However, it has been suggested that
the criterion for elevated blood levels in children is too high
in adults based on substantial evidence [108].
There is a great public health concern in the eﬀects of
environmental lead exposure on cardiovascular outcomes
[109], especially the role of chronic low-level lead exposures
in the pathogenesis of CVD [110]. Population-based studies
on the cardiovascular eﬀects of lead have focused largely on
the association with hypertension, a leading risk factor for
CVD morbidity and mortality [111]. The interrelationship
between blood lead and blood pressure has been reviewed
and reported to be statistically signiﬁcant [112]. However,
a major drawback of this meta-analysis was the inclu-
sion of lead exposed subjects with occupational and non-
occupationalsources.Inasmuchothercardiovascularevents
including, coronary heart disease, stroke, and peripheral
arterial disease, were found to be associated with lead ex-
posure, the exact role of lead in CVD is still incompletely
understood [25].
7.2.1. Epidemiological Evidence. Lead intoxication has been
shown to promote atherosclerosis in experimental animals
[113]. Experimental ﬁndings in several species suggest that
lead acts at multiple sites within the cardiovascular system
[114]. Depending on the magnitude and the duration of lead
exposure, cardiac and vascular complications are potentially
life threatening. There are also indications that chronic
lead exposure may aﬀect systemic lipid metabolism [113].
Current evidence on lead-induced oxidative stress has been
based mostly on in vitro experiments [115] or studies
conducted in animals [116]. Chronic exposure has been
also linked to atherosclerosis and increased cardiovascular
mortality in man [117]. Several epidemiological studies
amongworkerswithhighoccupationalexposuretoleadhave
reported associations between lead exposure and oxidative
stress markers [118]. Recent epidemiological studies have
reported that low level lead exposure has a graded associ-
ation with several disease outcomes such as hypertension
and peripheral artery disease [119–121]. Although such
diseasesincludecomponentsofoxidativestress,therelevance
of oxidative stress to lead-related disease with low-level
exposure has been criticized because mechanistic studies
have been conducted at levels not typically observed in
general population. The association between blood lead
level and elevated blood pressure is still subject to con-
troversy. However, lead has been postulated as causing
hypertension by inducing an alpha adrenoceptor-mediated
vasoconstriction [122]. Increased renin and angiotensin
production, due to the nephrotoxicity of lead, could also
be a factor in causing elevated blood pressure [123]. Lead-
mediated impaired vasomotor tone, as a result of reduced
NO bioavailability, may contribute to hypertension and
hence atherosclerosis. Disturbances in calcium metabolism,
particularly its role in modulating blood pressure through
control of vascular tone, have been suspected as the likely
mechanism of action. Moreover, cumulative evidence from
clinical studies on the association between blood lead levels
and CVD has yielded conﬂicting results [120, 124, 125].
Lack of consistency in ﬁndings could be due to diﬀerences
among study cohorts in exposure/ toxicokinetic factors (e.g.,
dose, timing), in pattern of environmental characteristics
(e.g., coexposures, comorbidity, developmental supports,
assessment setting), in distribution of genetic characteristics
that aﬀect lead metabolism and racial background or the
health worker eﬀect [126, 127]. Methodological limitations
are a great threat to validity of epidemiological studies, for
example, misclassiﬁcation of exposure and/or outcome may
have occurred and resulted in further underestimation of the
association of lead and cardiovascular end points.
Therefore, the results of these studies should be consid-
ered within the context of its possible limitations such as, the
reliance on a single lead measurement, the use of diﬀerent
exposure measures, or residual confounding by sociodemo-
graphic determinants of lead exposure. The healthy worker
eﬀect may also lead to underestimate or invalidate the risk
assessment of CVD.
7.2.2. Mechanism of Action. Acute lead exposure has been re-
ported to aﬀect cardiac function, and chronic lead exposure
has been shown to aﬀect the electrical and mechanical activ-
ity of the heart and to alter vascular smooth muscle function
in experimental animals [128] .M a n ys t u d i e sh a v ef o c u s e d
on metal-induced toxicity and carcinogenicity, emphasizing
their role in the generation of reactive oxygen and nitrogen
species in biological systems. Metal-mediated formation of
free radicals may enhance lipid peroxidation and changes in
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oxygen species production, lead may trigger a cycle of ox-
idative stress and inﬂammation in the target tissues [129].
Depletion of cells’ major sulfhydryl reserves seems to be an
important indirect mechanism for oxidative stress that is
induced by redox-inactive metals [130].
The precise mechanism explaining the hypertensive ef-
fect of lead exposure is unknown. However, an inverse as-
sociation between estimated glomerular ﬁltration rate and
blood lead levels below 5μg/dL has been observed in
general population studies [108], indicating that lead-
induced reductions in renal function could play a major
role in hypertension. Other potential mechanisms include
enhancedoxidativestressinthepathogenesisoflead-induced
hypertension [131]. Although elevated blood pressure and
impaired renal function are proposed mechanisms that
mediate the eﬀects of lead on clinical cardiovascular out-
comes, other mechanisms are likely to be involved.
As has been mentioned earlier, CVD progression and
outcomes rely to some degree on the presence of inﬂamma-
tion [34]. Increased expression and production of inﬂamma-
torymarkersinassociationwithleadexposurehavealsobeen
found in humans [132]. Although these ﬁndings suggest a
possible involvement of oxidative stress in the pathophysiol-
ogy of lead toxicity, it is not clear whether these alterations
are the cause of the oxidative damage or a consequence of it.
Various in vitro and in vivo studies have explored the
underlying mechanisms by which chronic low level lead
exposure can raise arterial pressure, thereby CVD develop-
ment.Thesestudieshaveidentiﬁedtheinvolvementofoxida-
tivestressandinﬂammation[133],bypromotingendothelial
dysfunction [134], promoting vascular smooth muscle cells
proliferation and transformation [135], and impairing NO
homeostasis [136]. NO plays multiple physiological roles in
vascular wall including endothelium-mediated vasodilata-
tion, inhibition of platelet activation and smooth muscle cell
migration and proliferation, and suppression of the proin-
ﬂammatory mediators through NF-κB inactivation [32].
Diminished NO bioavailability may be caused by inhibition
of the endothelial NO synthase (eNOS) expression, a lack
of substrate or cofactors for eNOS, alterations of cellular
signaling such that eNOS is not appropriately activated, and,
ﬁnally, NO inactivation through interaction with reactive
oxygenspecies(O2
–).Furthermore,antioxidanttherapywith
v i t a m i nEa n da s c o r b i ca c i ds u p p l e m e n t a t i o nr a i s e dN O
availabilityinratswithlead-inducedhypertensioncompared
with no eﬀect upon blood pressure or tissue nitrotyrosine (a
marker of NO oxidation) in control rats [137]. These ﬁnd-
ings support the notion that exposure to lead causes func-
tionalNOdeﬁciency,inpartbyreactiveoxygenspeciesmedi-
atedNOinactivation.GiventhecriticalroleofNFκBinman y
aspects of atherogenesis, their activation by lead exposure
may play a part in the development of hypertension [138].
Experimental studies have suggested plausible mecha-
nisms whereby lead contributes to alterations of vascular
resistance and hypertension by causing disturbances in cal-
cium metabolism, particularly its role in modulating blood
pressure through control of vascular tone [139]. It has been
shown that lead can compete with calcium for the transport
bychannelsandpumpsinvolvedinmovementsofionsacross
the cell membrane and between cytoplasm, endoplasmic
reticulum, and mitochondria, thereby contributing to the
changes in cytosolic calcium ions known to be involved in
the regulation of vascular tone and vascular smooth muscle
contraction [140]. In addition, lead may aﬀect the calcium-
mediated control of vascular smooth muscle contraction via
serving as a substitute for calcium in calcium-dependent
signaling pathways by interacting with calmodulin and
calcium-dependent potassium channels [141]. Uncontrolled
release of calcium ions from the mitochondria has been
reported to occur during oxidative stress, a condition re-
sulting from the imbalance between the production of free
radicals and the counteraction by the cellular antioxidant
defenses[142].Leadmayalsoincreasepressorresponsiveness
to catecholamines, which may be a consequence of the lead
eﬀect on the intercellular messenger protein kinase C and its
role in smooth muscle contraction [143].
7.2.3. Combination of Gene-Environmental-Nutrient Interac-
tions. The exact mechanism by which lead induces oxidative
stress is not fully understood. However, at least certain cir-
cumstances (i.e.) including genetic predisposition, nutri-
tional inﬂuence, and environmental coexposure are expected
to interact and therefore are linked in an attempt to explain
such mechanism(s) of lead-induced toxicity.
Nutrition is an important susceptibility factor suggesting
that people with poor nutrition are particularly susceptible
[144]. Nutritional factors are often considered as important
modiﬁer of the metabolism and toxicity of lead [145]. This
can be explained by lead-induced oxidative stress, an eﬀect
that is augmented by lead-induced inhibition of several of
the antioxidant systems. This supposition was conﬁrmed
by studies which showed extensive accumulation of reactive
oxygen species (as markers of NO oxidation) in kidney,
brain, and cardiovascular tissues of untreated rats with lead-
induced hypertension and its reversal by antioxidant therapy
using high doses of vitamin E and vitamin C [137]. Essential
elements, such as calcium, zinc, iron, selenium, and antiox-
idant vitamins have shown to counteract the toxic eﬀects of
lead [146]. The joint eﬀect of high lead and low antioxidant
micronutrients levels should be considered as a modifying
factor in atherosclerosis, and their role in determining risk
should be investigated. These nutritional facts suggest a
novel approach to strategies for treating environmental lead
toxicity with micronutrients supplementations.
Certain genetic polymorphisms can lead to diﬀerences
in the level of susceptibility to adverse eﬀects of lead envi-
ronmental exposure. A better understanding of the genetic
factors that inﬂuence susceptibility to lead-induced intoxi-
cation could have signiﬁcant importance for public health
and intervention initiatives [147]. It is therefore reasonable
to conjecture that genetic disposition could lead to diﬀer-
ences in susceptibility to lead poisoning among the human
population. Researchers have identiﬁed a small number of
genes that induce susceptibility to environmental toxicants,
and much interest has developed in that area. Three poly-
morphic genes have been identiﬁed that can inﬂuence the
bioaccumulation and toxicokinetics of lead in humans, the10 Journal of Toxicology
6-aminolevulinicaciddehydratase(ALAD)gene,thevitamin
D receptor (VDR) gene, and the hemochromatosis (HFE)
gene.
One of the most important mechanisms of lead toxicity
is its inhibitory eﬀect on the heme biosynthetic pathway
enzymes; ALAD and ferrochelatase. Polymorphisms of the
ALAD gene have been associated with the accumulation and
distribution of lead in the blood, bone, and internal organs.
Lead binds the enzyme’s sulfhydryl group, which normally
binds zinc, preventing the binding of aminolevulinic acid
(ALA), the normal substrate. ALAD activity has been used
as a sensitive marker for the detection of lead intoxication
[148]. Concomitantly, ALA accumulates in blood and urine
and may contribute to lead-induced toxicity to the brain. Its
urinary excretory level has been used as a biomarker for early
lead exposure [149].
1α25(0H)2D3 (calcitriol),thecirculatoryformofvitamin
D in blood, is involved in calcium absorption. It binds to
VDRs in gut, kidneys, and bone. The VDR gene has been
implicated in the control of calcitriol levels in serum, which
normally regulates calcium absorption and can in turn aﬀect
lead levels. The high-aﬃnity VDR appears to activate genes
that encode calcium-binding proteins such as calbindin-D,
which is involved in intestinal calcium transport. Because of
their similar biochemical nature as divalent cations, calcium
and lead often aﬀects the normal function of calcium-
dependent systems [150]. These data suggest that calcium
and lead are cotransported through the gut into the blood,
and from there the two metals may be codistributed to
calcium-rich tissues such as the bone [151]. In addition,
lead toxicity may impair calcitriol hormonal synthesis in the
kidney, therefore interfering with calcium absorption [152].
Together, these data show that the interactions between lead,
calcium,andcalcitriolarecomplexandinducemodiﬁcations
of mineral and vitamin levels.
Hemochromatosis is the genetic form of iron load in
whichpatientslackafunctionalHFEproteininvolvediniron
homeostasis due to mutations in the HFE gene that may also
inﬂuence lead absorption [153]. At least two mechanisms
for the increased absorption of lead in hemochromatosis
gene carriers have been postulated. HFE protein binds to the
transferrinreceptor,reducingitsabilitytobindtotransferrin
and thus decreasing the absorption of iron in the gut [154].
Consistent with us, an important association has been made
between iron deﬁciency and increased lead absorption and
hence toxicity [144]. HFE protein may also inﬂuence the
expression of other metal transporters such as divalent metal
transporter in the gut that modify the absorption of other
metals in addition to iron [155]. This is compelling data that
iron status inﬂuences lead toxicity.
Therefore, diﬀerences in the expression rate of the
polymorphic genes in response to nutritional inﬂuence over
their activities are highly suggestive but not conclusive in
considering environmental link with both genetic and di-
etary elements.
7.3. Cadmium. Cadmium is a widespread toxic metal con-
taminating many areas, either naturally or because of in-
dustrial use as in regions of Belgium, Sweden, UK, Japan,
and China. Modes of exposure are either through intake
of contaminated food (e.g., leafy vegetables, grains, organ
meats, and crustaceans), drinking water, or by inhalation
of polluted air or occupational in industries. Cadmium
presence in tobacco smoke further contributes to human
exposure as the tobacco leaves accumulate cadmium in
a manner similar to certain food from plants. Smokers
have approximately twice the cadmium body burden of
nonsmokers [156].
Regardless of the route of exposure, cadmium is eﬃ-
ciently retained in the organism and remains accumulated
throughout life. In addition to its cumulative properties,
cadmium is also a highly toxic metal that can disrupt a
number of biological systems, usually at doses that are much
lower than most toxic metals. A European risk assessment
report proposed that cadmium deleterious eﬀects may occur
at levels as low as 0.5μg/g creatinine based on data from the
most recent European studies [157].
A threshold value for safe dietary cadmium exposure
level has been set to be below 2.5μg/kg body weight per
week [158]. Furthermore, it was noticed that subgroups of
the population, such as vegetarians, women in reproductive
phase of life, smokers, and people living in highly contami-
nated areas may exceed the tolerably weekly intake by about
2-fold.
Chronic cadmium exposure is associated with hyperten-
sion and diabetes [24, 159]. However, the exact inﬂuence
of cadmium on the cardiovascular system remains contro-
versial. More importantly, these data show that cadmium
may exert eﬀects on the cardiovascular system at extremely
low exposure levels. In vitro studies data revealed that low-
dose cadmium levels (well below toxic concentrations) may
contribute to the initiation of pathophysiological changes in
the vessel wall [160].
Several important reviews have outlined the cardiovas-
cular eﬀects of cadmium in man. Evidence from prospective
studies reveals potential causal relationships of blood cad-
mium and blood pressure but not the relationship between
urinary cadmium and hypertension [161]. An inverse rela-
tionshipbetweenurinarycadmiumlevelsandbloodpressure
was reported in another meta-analysis [24]. These para-
doxical relationships were evident in both high- and low-
exposure populations and thus contradict earlier assump-
tions that this inverse association only reﬂected higher
cadmium exposures. A limitation common to all these stud-
ies and thus to this meta-analysis is that the outcome
was not consistently deﬁned across studies; therefore, lack
of association might reﬂect outcome misclassiﬁcation.
7.3.1. Epidemiological Evidence. The cardiovascular eﬀects
of cadmium have been observed in in vitro studies and in
experimentalanimalmodels[162,163].Increasedcardiovas-
cular mortality was documented for men living in areas with
increased potential for cadmium exposure, thus suggesting
that cadmium is at least a comorbidity factor if not
a causative factor [57].
Epidemiologic studies of the association of environmen-
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inconsistent. Discrepancies across epidemiological studies
might be due to that some studies have strengths including
prospective designs [164], blood pressure values entry as
a continuous variable to avoid outcome misclassiﬁcation
bias [165], while other studies, however, have been limited
by small sample sizes, lack of adjustment for potential
confounders, and lack of standardization of blood pres-
sure measurements [161]. Sample selection considerations
and exposure measurement error are additional limitations
in these studies [166].
Cadmium exposure also potentiates some diabetic com-
plications related to renal tubular and glomerular function.
Epidemiological evidence shows higher susceptibility for
persons with diabetes to develop cadmium induced renal
dysfunction[167].AstudyexaminingthedatafromNational
Health and Nutrition Examination Surveys (NHANES) re-
ported a signiﬁcant association between high urinary cad-
mium levels and high fasting blood glucose levels in a dose
dependent manner, as well as more susceptibility among
the diabetic subjects for the cadmium-induced renal eﬀects
[168]. Thus, suggesting that cadmium may be a cause of
prediabetes and diabetes mellitus in humans. On the con-
trary, less agreement exists about the clinical signiﬁcance
and predictivity of the urinary cadmium level as a surrogate
marker of body content and the tubular biomarkers of renal
dysfunction.
NHANES data reported that peripheral arterial disease
might be associated with blood and urinary cadmium, thus
suggesting that cadmium is involved in arterial dysfunction
[58]. Diﬀerent cadmium biomarkers may provide diﬀerent
information regarding the timing and source of exposure.
However, the use of these biomarkers has been inconsistent
across epidemiological studies. In general, urinary cadmium
level reﬂects the body burden over long-term exposure
among people with lower, nonoccupational exposures, and
blood cadmium, with a half-life of 3-4 months, is considered
an indicator of recent exposure [56]. Alternatively, urine
and blood cadmium are sometimes considered biomarkers
of ongoing and long-term cadmium exposure, respectively
[156].
Cadmium may exert its adverse cardiovascular eﬀects
by promoting atherosclerosis and by inducing disadvan-
tageous cardiac functional and metabolic changes [169].
Recently blood cadmium level was independently associated
with myocardial infarction [170] and early atherosclerotic
vessel wall thickening as estimated by intimamedia thickness
ratio [171]. In contrast no correlation was observed between
blood cadmium and measures of arterial function [172].
Epidemiological studies did not ﬁrmly establish a link
between cadmium and CVD due to confounding eﬀects, for
example, coexposure to other heavy metals, unadjusting for
smoking habits. Moreover, disagreement between exposure
studies might be attributed to the use of diﬀerent exposure
measures with diﬀerent pathophysiological signiﬁcance of
blood and urinary cadmium.
7.3.2. Mechanism of Action. It has been long hypothesized
that cadmium may contribute to the pathogenesis of CVD
via a number of proposed mechanisms, such as partial
agonism for calcium channels, direct vasoconstrictor action,
and inhibition of vasodilator substances such as NO [173].
The exact mechanism whereby cadmium aﬀects the cardio-
vascular system is not known, although experimental studies
have suggested several plausible possibilities [174]. Because
cadmium levels used in experimental models are much
higher than exposure in the general population, the rele-
vance of these mechanisms to the pathogenesis of CVD is
uncertain. A primary mechanism for cadmium toxicity is its
eﬀect on cells which has been ascribed to the oxidative stress
promoting cadmium action, as observed in vivo [162], and
mostimportantly,thedepletionofglutathioneandalteration
of sulfhydryl homeostasis [42], thus indirectly increasing
oxidative stress and lipid peroxidation [175]. However,
results from other studies were inconclusive in supporting
a direct eﬀect of cadmium [171]. It has been argued that
reasons are the concentration of cadmium applied, as well as
the upregulation of antioxidant defense in endothelial cells
in response to cadmium may deﬁne the presence of reactive
oxygen species in endothelial cells [176].
Cadmium is absorbed mainly through the respiratory
and digestive tracts and under conditions of chronic expo-
sure; cadmium is transported in blood bounded mainly to
metallothionein. Metallothioneins are heavy metal-binding
proteins that can protect against heavy metal toxicity and
oxidative stress. The vascular wall has been shown to be a
target organ of cadmium deposition [177]. However, other
important issues are not yet fully understood, like the form
of cadmium which is taken up by cells (i.e., free ion or
protein bound), their expected amounts in circulation, and
the precise uptake route of cadmium by the cells. Albeit,
several ion channels and transporters have been described to
transport cadmium across the plasma membrane, for exam-
ple, calcium-channels [178], plasma membrane-associated
DMT-1 [179]; it is unclear whether these mechanisms are
also active in endothelial cells.
Apartfromdirectuptakeofcadmiumbyendocytosisinto
cells of the vessel wall, cadmium may also be taken up by
cells of the immune system and may enter the vessel wall
via inﬁltration of the vessel wall, for example, by cadmium-
laden monocytes [180]. Given the fact that the critical role
of monocytes/macrophages transdiﬀerentiate into foam cells
and necrotic foam cell death in many aspects of endothelial
dysfunction, their excessive production by cadmium plays a
majorpartintheinitiationandpromotionofatherosclerosis.
Cadmiumuptakecouldalsooccurviadisruptionofendothe-
lial integrity and subsequent cadmium-mediated endothelial
cells death. Formation of gaps between endothelial cells
usually follows, allowing for cadmium diﬀusion from the
blood stream into the medial layer [59]. Vascular wall cells
seem to allow for a suﬃcient transport of cadmium across
the endothelium and are capable of retaining high amounts
of cadmium mainly in the smooth muscle cells [177]. Eﬀects
on smooth muscle cells include an interaction with ion
homeostasis and Ca2+ ﬂux, cytotoxic eﬀects, but also the
stimulation of smooth muscle cell proliferation at low cad-
mium concentrations [181], thus, allowing for subsequent
lipid accumulation in the vessel wall and a modiﬁcation12 Journal of Toxicology
of lipid proﬁles towards a more atherogenic state [34].
Ampleofevidencepinpointstheinductionofendothelialcell
death by cadmium which is thought to be fundamental in
the atherosclerosis-promoting properties of cadmium [59].
However, data on the mode of cell death are contradictory.
Cadmium-induced endothelial necrosis would, in addition
to damaging the integrity of the vascular endothelium, also
contribute to vascular inﬂammation.
7.3.3. Combination of Gene-Environmental-Nutrient Interac-
tions. There is evidence for nutritional inﬂuence over the
rate of intestinal absorption of cadmium (i.e.) increased cad-
mium if the nutritional intake of calcium, iron, or zinc
is low [182]. Moreover, cadmium exposure interferes with
the homeostasis of other metals, and, reciprocally, cadmium
eﬀects depend on the body status for some essential metals
[183]. Cadmium is acquired by transport mechanisms
developed for essential metals, most likely to be one of
the following divalent cations: zinc (Zn2+), iron (Fe2+),
manganese (Mn2+), and calcium (Ca2+). It follows that the
mechanisms of cadmium toxicity must be considered with
respect to the systems regulating diﬀerent aspects of these
metals turnover in the body. Considering that cadmium
substitutions at the metal sites of metalloproteins were
performed in vitro only and the scarcity of data demonstrat-
ing such occurrences in vivo, care should be taken before
interpreting cadmium toxicity data with a simple molecular
explanation. Yet, cadmium replacement of other metals in
cellular proteins does occur as in metallothionein [184].
Furthermore, metallothionein may, apart from binding
and thereby inactivating the major portion of cadmium ions,
also serve as a source for constant levels of intracellular free
cadmium ions [59]. On the other hand, recent epidemiolog-
ical studies are indicating the protective eﬀect of the antiox-
idant property of zinc against cadmium toxicity probably by
metallothionein stimulation [171]. To date, mechanisms of
cadmium-zinc interaction and their impact on the oxidative
status derived from in vitro studies and limited number of
human studies [185]. The wide variety of diﬀerent doses,
dose ratios, element administration modes, and exposure
lengths of cadmium and zinc often yielded contradictory
results.
Cadmium intoxication results in an induction of met-
allothionein gene transcription and an increase in metal-
lothionein production [186]. Cadmium also aﬀects several
genes involved in the stress response to pollutants or toxic
agents, as in heat shock proteins that are highly implicated in
cardiovascular pathophysiology [187]. Many genes involved
in cell cycle regulation are overexpressed after exposure to
cadmium, and many proteins are upregulated; for example
cadmium stimulates the expression of ICAM-1 [188].
Cadmiumaﬀectscellcycleprogression,proliferation,dif-
ferentiation, DNA replication, and repair as well as apoptotic
pathways [147, 158]. In addition to its role as a generator
of reactive oxygen species, involved in the occurrence of
DNA damage, cadmium may also reduce cellular antiox-
idants levels [189]. The reduction of activities of several
antioxidant proteins (catalase, glutathione reductase, total
glutathione), mediated by cadmium, may cause the accumu-
lation of reactive oxygen species in cells [190]. Indirectly, this
overproductionofoxidantmoleculesmaybealsoresponsible
for the generation of abnormal or misfolded proteins and
lipid peroxidation [191].
7.4. Mercury. Mercury is an environmental pollutant that
presents at low levels in water systems (lakes, rivers, oceans,
etc.) but bioconcentrate in the aquatic food chain, as in some
ﬁsh species (particularly fatty ﬁsh) that can also contain
other environmental contaminants such as polychlorinated
biphenyls, dioxins. The global cycle of mercury begins with
the evaporation of mercury vapor into the atmosphere.
More concern about the release of volatile mercury that
will become part of the local mercury cycle and repollute
the environment again, into the ambient air. Mercury exists
in three forms: elemental or metallic mercury, inorganic
mercury compounds, and organic mercury. It is used in
glass thermometers as elemental mercury and in dental
amalgam ﬁllings as inorganic mercury compounds. Organic
mercury is found mainly in ﬁsh as methylmercury and in
some vaccines as ethylmercury (thimerosal).
The US Environmental Protection Agency has reduced
the recommended safe daily intakes of methylmercury from
0.5 to 0.1μg/kg body weight [192]. In the absence of advi-
sories for local waters which are available, US Environmental
Protection Agency and US Food and Drug Administration
have also issued recommendations on ﬁsh consumption
among women of childbearing age and young children
based on methylmercury content; commonly eaten ﬁsh and
shellﬁsh that have lower levels of mercury should be limited
to two meals per week.
In recent years, more attention has been given to other
health eﬀects of methylmercury exposure, following the epi-
demiological ﬁndings from Finland, conﬁrming that high
mercury content in hair was associated with an increased
progression of atherosclerosis and risk of CVD [193]. It is
noteworthy that these adverse eﬀects on CVD have been
observed at methylmercury levels much lower than those
associated with neurotoxicity.
7.4.1. Epidemiological Evidence. Mercury exposure has been
shown to promote atherosclerosis both in vivo and in vitro
[194, 195]. The potential harmfulness of mercury in CVD
was ﬁrst observed in the Kuopio Ischemic Heart Disease
Risk Factor (KIHD) study cohort [26]. Several follow-up
studies on KIHD study cohort conﬁrmed their observations
[196, 197]. In agreement with KIHD study results, it has
been suggested in the European Multicenter Case-Control
Study on Antioxidants, Myocardial Infarction, and Cancer
of the Breast (EURAMIC) study, that high mercury content
may diminish the beneﬁcial eﬀects of ﬁsh consumption
on cardiovascular health [198]. Likewise, in the Health
Professionals Follow-up Study (HPFS), increased cardio-
vascular risk following mercury exposure among dentists,
who have an occupational exposure to mercury vapor via
amalgam, was consistent with the results from the KIHDJournal of Toxicology 13
and EURAMIC studies [199]. However, these ﬁndings were
not supported by prospective studies conducted in Sweden
[200]. Unlike the previous studies, this population included
women and had too low mercury levels, and the range
of mercury may have been too narrow to exert suﬃcient
statistical power to detect an association. Apparent discrep-
ancies might be attributed to methodological limitations
which are very common in epidemiological studies. In many
studies, there are uncertainties in exposure quantiﬁcation,
outcome ascertainment (e.g., misclassiﬁcation bias), and a
lack of information about exposure to other metals and
traditional risk factors that are of confounding eﬀects.
Current uncertainties in the role of mercury in the
development of hypertension and diabetes mellitus could
be attributed to limited available data [201, 202], and other
shortcomings like diﬀerences in study design or exposure
assessment, lack of sensitive biomarker, and lack of standard
criteria for hypertension and diabetes assessment.
7.4.2. Mechanism of Action. Mercury-induced oxidative
damage has been observed both in vivo and in vitro, includ-
ing myocardial tissues. The mechanisms by which mercury
exerts its cardiovascular eﬀects are not fully understood.
However, exposure to mercury can lead to oxidative stress
induction [203], sulfhydryl groups depletion [204], altered
mitochondrial function, and apoptosis [205].
Mercury-induced redox imbalance may be caused by
either increased reactive oxygen species generation or by
reduced antioxidants defense capacity. This is supported by
observations that antioxidants, both enzymatic and nonen-
zymatic, can protect against methylmercury toxicity [194].
However, most information is currently derived from animal
experimental models and thus implications for human
populations consuming mixed diets can only be speculative
at this time.
Mercury can bind to and thus forming complexes
with thiol-containing compounds targeting proteins such as
glutathione [206], which plays a critical role in regenerating
vitamins C and E from their oxidized byproducts. In addi-
tion, glutathione-mercury complexes appear to be the pri-
mary form in which mercury is transported and eliminated
from the body, further decreasing cellular defenses against
oxidation. Furthermore, its high aﬃnity for thiol groups and
its ability to bind selenium to form an insoluble complex
could reduce antioxidative defenses and promote free radical
stress and lipid peroxidation in the human body [26]. This
interaction between mercury and selenium may represent
one mechanism through which mercury increases the risk of
CVD, for instance by reducing the bioavailability of selenium
or by impairing the activity of glutathione peroxidase. On
the contrary, reciprocal interactions are expected, that is,
high selenium levels could protect against excess mercury.
However, at present, there is very little evidence from human
studies to support the hypothesis.
It has been demonstrated that mercury alters the
structural integrity of the mitochondrial inner membrane,
resulting in loss of normal cation selectivity [194].
Other possible mechanism by which mercury can pro-
mote lipid peroxidation and subsequent atherosclerosis is
by inhibiting the activation of NF-κB. Mercury may bind
to the sulfhydryl groups present in NF-κB and thus impair
the activation of NF-κB and attenuate its eﬀects on gene
expression [207]. Mercury has been also shown to suppress
NO production in in vitro studies by inhibiting the NF-
κB pathway and, in that way, inactivating the expression of
inducible nitric oxide synthase (iNOS) gene [208]. iNOS
catalyzes the production of NO, which has an important
role in the maintenance of vascular regulation and immune
system [94]. There is some evidence from in vitro studies
that mercury can induce changes in platelet aggregation by
binding to the thiol groups present in the platelet membrane
[209]. However, the exact role of mercury in CVD-related
endothelial, inﬂammatory, and immune functions warrants
further investigation.
7.4.3. Combination of Gene-Environmental-Nutrient Interac-
tions. Thecardiovasculareﬀectofmercuryatlowerexposure
levels is still subject to controversy. As in the limited
understanding of the mechanisms of mercury toxicity [210],
nutritional consideration may often be concurrent with
or may be additive to genetic predisposition to mercury
exposure [211]. However, more focus was attributed to
m e r c u r yr e t e n t i o nb yv a r i o u so r g a n si ne ﬀorts to explain
nutrient mercury interactions [212].
Even though there is ample evidence on food interaction
withmercurymetabolismatthephysiologiclevel,lesscertain
are the eﬀects of nutrients that might inﬂuence bioavailabil-
ity,toxicodynamics,andtransporttotargetorgansandinﬂu-
ence the immunologic, biochemical, or cytologic functional
responses to mercury.
Food-like ﬁsh has been implicated in the alteration of
mercury metabolism. In terms of macronutrient intakes
such as fat intake, a positive correlation between dietary
mercury and low-density lipoprotein cholesterol levels was
observed [213]. Unsaturated fatty acids were also correlated
withmercuryexposureinpopulationsfrequentlyconsuming
seafood and ﬁsh [198]. However, evidence for protective
or antagonistic eﬀects is often complex and highly depen-
dent on metabolic conditions. Studies on the eﬀects of
macronutrients on mercury metabolism are expected to
shed some light on possible interactions between diﬀerent
nutrientsastheyhavebeenshowntomodulatetoxicokinetics
and dynamics of mercury metabolism [214].
Micronutrientsmaymodifymercurytoxicityduetotheir
antioxidant properties. Certain phytochemicals found in the
diet reportedly protect against methylmercury toxicity [215].
Such a role is subject to controversy as some antioxidants
were found to enhance mercury toxicity in vitro [216]. It is
still unknown if these eﬀects are related to antioxidant/pro-
oxidant activity or other aspects of mercury metabolism.
Of all trace elements, selenium, because of protective eﬀects
observed in animal studies, has received the most attention
as a potential protector against methylmercury toxicity in
populations consuming seafood [217]. Mercury has a high
aﬃnity for selenium, and it readily binds selenium to form14 Journal of Toxicology
insoluble mercury selenide complexes [218]. Through this
interaction, mercury could reduce the bioavailability of sele-
nium and impair the activity of glutathione peroxidase, thus
promoting lipid peroxidation and, subsequently, atheroscle-
rosis. Nonetheless, the combinationofhighmercuryandlow
selenium was not associated with higher CVD risk [199].
These observations could have been due to limited number
of subjects in stratiﬁed analysis.
Environmentally induced changes in gene regulatory
mechanisms along with dietary interactions may exacer-
bate mercury intoxication. Metallothionein protein, rich in
sulfhydryl groups, helps in scavenging and reducing the toxic
eﬀects of mercury. Metallothionein induction is not only
seen with mercury but various other metals like cadmium,
zinc, and copper [219]. Toxic eﬀects of mercury also induce
a number of stress proteins which include heat shock
proteins and glucose-regulated proteins that have also been
implicated in cardiovascular pathophysiology [220].
8. Conclusions
Detrimental eﬀects of heavy metals on the cardiovascular
system have been less well deﬁned. A potential proathero-
genic eﬀect even if modest compared to other traditional
risk factors would have a signiﬁcant impact in sensitive
population groups. However, some issues need to be taken
into consideration before one can draw any deﬁnitive con-
clusions. For example, adjustment for confounding variables
has been performed in some studies; however, it does not
ensure the independence of their association, as it is not
possible to measure every conceivable variable.
Studies summarized in this review point to the harmful
eﬀectsofheavymetalsexposureonthedevelopmentofCVD.
Heavy metals are suspected of inducing pathophysiological
changes relevant to atherogenic events including increased
oxidative stress, inﬂammatory response, and coagulation
activity. In addition, there are several suggested biological
mechanisms that support this hypothesis. The combination
of a susceptible genetic background and dietary elements
along with environmental coexposure to heavy metals may
also explain some aspects of their cardiovascular eﬀects.
However, the exact mechanism of CVD induced by
heavy metals deserves further investigation either through
animal experiments or through molecular and cellular
studies. Such study designs are optimal to deﬁne the
cellular and subcellular mechanisms through which they
aﬀect the cardiovascular system. Basic insights from the
science of cell and molecular biology coupled with improved
analytical capabilities have led to the development of better
biomarkers embracing the genetic ﬁeld. There is also a
pressing need for the use of sensitive biomarkers in early
detection of low-level exposures from new technologies such
as nanotechnology. The genetic mechanisms investigated in
these studies may also oﬀer new avenues for risk assessment
research. Regarding experimental animal models, doses and
exposure should be adjusted to long-term low exposure
levels that are usually found in human population. Findings
based on these studies can lead to the identiﬁcation of
a coherent and consistent biological research pathway for
biomarker validation and acceptance into public health
practice. Furthermore, large-scale prospective studies with
followupongeneralpopulationsusingappropriatebiomark-
ers and cardiovascular endpoints might be recommended to
identify the factors that predispose to heavy metals toxicity
in CVD.
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